Innovative Ideal (541983)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE is positive at 5.79%, showing some capital efficiency despite the net loss.
• Latest quarter still has ₹1 crore of sales, providing a small revenue base to build from.
• Market cap of ₹29 crore means a modest absolute improvement could have a disproportionate impact.
• Price near the 52-week high of ₹27.65 suggests recent market interest, though not a fundamental strength.

Concerns

• Latest quarter net loss of ₹5 crore is five times the quarterly sales of ₹1 crore, indicating unsustainable cash burn.
• Profit growth of -254.69% and Piotroski F-score of 3/9 point to severe financial deterioration.
• No book value, ROE, debt/equity, or promoter holding data makes valuation impossible.
• Zero dividend and zero sales growth provide no income or growth cushion.

AI Analysis

This is precisely the kind of small, opaque name I would normally walk past. Innovative Ideal sells for ₹25.74 with a market cap of ₹29 crore, but the latest quarter tells a grim story: sales of just ₹1 crore and a net loss of ₹5 crore. In one quarter it lost five times its revenue. Profit growth is -254.69%, and reported P/E is 0.00 because earnings are negative. There is no book value, no ROE, no debt-equity ratio, no promoter holding details—the data is simply insufficient for any intelligent valuation. A Piotroski F-score of 3 out of 9 reinforces my caution: the financial health is weak, and the balance sheet signals are poor. ROCE of 5.79% is the only positive number, but that is far too low and cannot offset a ₹5 crore quarterly loss. The company has paid no dividend, and sales growth is 0.00%. When I look for a moat, I see none. This is a diversified commercial services business with no pricing power evident and no evidence of a competitive advantage. The market cap is only ₹29 crore, so any large order or restructuring could move the stock, but that is speculation, not investing. The price is near the 52-week high of ₹27.65, up from ₹12.00, yet the underlying fundamentals have worsened—that is a warning, not a validation. As Graham would say, price is what you pay, value is what you get. Here I cannot calculate value with the data available. I would pass unless the company shows tangible improvement in sales, a sharp reduction in losses, and clean financial disclosures. This is a possible turnaround watch, not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer